Tasly Pharmaceutical Group Co Ltd (600535) — Capital Reinvestment Ratio
Tasly Pharmaceutical Group Co Ltd (600535) has a Capital Reinvestment Ratio of 0.21x as of December 2025, meaning it reinvests 0% of its operating cash flow (CN¥552.13 Million) in capital expenditures (CN¥117.78 Million). See how leveraged is Tasly Pharmaceutical Group Co Ltd's balance sheet to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Tasly Pharmaceutical Group Co Ltd Capital Reinvestment Ratio (2001–2025)
This chart tracks Tasly Pharmaceutical Group Co Ltd's Capital Reinvestment Ratio across 24 annual periods. Check Tasly Pharmaceutical Group Co Ltd cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Tasly Pharmaceutical Group Co Ltd (2001–2025)
Year-by-year Capital Reinvestment Ratio for Tasly Pharmaceutical Group Co Ltd from 2001 to 2025. For live market cap and broader valuation context, see 600535 market cap.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.27x | CN¥1.42 Billion | CN¥381.26 Million | ▼ -4.6% |
| 2024 | 0.28x | CN¥2.01 Billion | CN¥564.94 Million | ▲ +8.0% |
| 2023 | 0.26x | CN¥2.58 Billion | CN¥668.82 Million | ▲ +47.1% |
| 2022 | 0.18x | CN¥2.29 Billion | CN¥403.45 Million | ▼ -13.5% |
| 2021 | 0.20x | CN¥2.80 Billion | CN¥571.73 Million | ▼ -10.6% |
| 2020 | 0.23x | CN¥1.79 Billion | CN¥408.81 Million | ▼ -47.5% |
| 2019 | 0.43x | CN¥1.68 Billion | CN¥730.78 Million | ▼ -16.7% |
| 2018 | 0.52x | CN¥1.49 Billion | CN¥780.10 Million | ▲ +14.8% |
| 2016 | 0.45x | CN¥1.15 Billion | CN¥524.68 Million | ▼ -79.0% |
| 2015 | 2.17x | CN¥340.00 Million | CN¥737.84 Million | ▲ +77.3% |
| 2014 | 1.22x | CN¥616.76 Million | CN¥754.93 Million | ▼ -36.1% |
| 2013 | 1.92x | CN¥346.17 Million | CN¥663.56 Million | ▲ +103.1% |
| 2012 | 0.94x | CN¥413.31 Million | CN¥390.02 Million | ▼ -69.8% |
| 2011 | 3.13x | CN¥135.14 Million | CN¥422.58 Million | ▲ +643.6% |
| 2010 | 0.42x | CN¥395.05 Million | CN¥166.13 Million | ▲ +44.1% |
| 2009 | 0.29x | CN¥400.39 Million | CN¥116.80 Million | ▼ -33.7% |
| 2008 | 0.44x | CN¥260.21 Million | CN¥114.51 Million | ▼ -51.5% |
| 2007 | 0.91x | CN¥221.55 Million | CN¥201.23 Million | ▼ -50.0% |
| 2006 | 1.82x | CN¥140.56 Million | CN¥255.41 Million | ▲ +31.8% |
| 2005 | 1.38x | CN¥214.90 Million | CN¥296.33 Million | ▼ -24.2% |
| 2004 | 1.82x | CN¥203.27 Million | CN¥369.62 Million | ▼ -67.4% |
| 2003 | 5.57x | CN¥59.00 Million | CN¥328.74 Million | ▲ +811.2% |
| 2002 | 0.61x | CN¥206.22 Million | CN¥126.09 Million | ▼ -57.1% |
| 2001 | 1.42x | CN¥83.77 Million | CN¥119.35 Million | — |